Success Metrics

Clinical Success Rate
100.0%

Based on 13 completed trials

Completion Rate
100%(13/13)
Active Trials
1(7%)
Results Posted
69%(9 trials)

Phase Distribution

Ph phase_2
6
43%
Ph phase_3
8
57%

Phase Distribution

0

Early Stage

6

Mid Stage

8

Late Stage

Phase Distribution14 total trials
Phase 2Efficacy & side effects
6(42.9%)
Phase 3Large-scale testing
8(57.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

13 of 13 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

14

all time

Status Distribution
Active(1)
Completed(13)

Detailed Status

Completed13
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 26 (42.9%)
Phase 38 (57.1%)

Trials by Status

completed1393%
active_not_recruiting17%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials
NCT02629159Phase 3

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

Active Not Recruiting
NCT03464136Phase 3

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

Completed
NCT02332590Phase 3

Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)

Completed
NCT02694523Phase 3

BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Completed
NCT02207231Phase 3

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

Completed
NCT02207244Phase 3

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment

Completed
NCT03823391Phase 2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

Completed
NCT01166282Phase 3

A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis

Completed
NCT02015793Phase 2

Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease

Completed
NCT00646178Phase 3

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

Completed
NCT00645892Phase 2

Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed
NCT00645814Phase 2

Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed
NCT00646386Phase 2

Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

Completed
NCT00645905Phase 2

Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14